Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
about
Understanding the interplay between host immunity and Epstein-Barr virus in NPC patientsViruses and human cancerThe murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralizationInfectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected miceSoluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeEpstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosisAntibody evasion by a gammaherpesvirus O-glycan shieldIdentification of glycoprotein gpTRL10 as a structural component of human cytomegalovirusThe bovine herpesvirus 4 Bo10 gene encodes a nonessential viral envelope protein that regulates viral tropism through both positive and negative effectsAn Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.Varicella-zoster virus as a live vector for the expression of foreign genes.Vaccination with murid herpesvirus-4 glycoprotein B reduces viral lytic replication but does not induce detectable virion neutralizationA gammaherpesvirus uses alternative splicing to regulate its tropism and its sensitivity to neutralization.Epstein-barr virus vaccines.Virus receptors: implications for pathogenesis and the design of antiviral agents.Epstein-Barr virus genetic variation in lymphoblastoid cell lines derived from Kenyan pediatric population.Epstein-barr virus: environmental trigger of multiple sclerosis?Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B.Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus MacaquesRational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteImmune regulation in Epstein-Barr virus-associated diseasesExpression of the Marek's disease virus (MDV) homolog of glycoprotein B of herpes simplex virus by a recombinant baculovirus and its identification as the B antigen (gp100, gp60, gp49) of MDV.Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragmentIdentification of the Epstein-Barr virus gp85 gene.A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.Roles of CD48 in regulating immunity and tolerance.Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cellsTwo major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene.Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virusAn Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200)A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus.Virion endocytosis is a major target for murid herpesvirus-4 neutralization.Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo.
P2860
Q26823898-62776D81-73CB-4AA4-B498-035EA57BA851Q27481175-6715BFEF-49D6-4793-A464-BE4834BD02D9Q33293521-929010A0-CE04-44C7-9A8B-04AECA76CB29Q33603682-14C7934E-569D-440E-8CB4-365E191B3D58Q33910354-A4707ACF-D5C0-4C7D-BAE2-F10881DD3531Q34058118-494A1601-A58B-4EC4-B19E-3B35CA12BE2BQ34076940-E31CBD9B-19C7-488B-BE1B-540DDF4EB1BCQ34082672-5C5E3EB5-0F15-41E3-952E-2E68FC73069CQ34328645-77973261-1C89-4D83-966B-7879D3DCCBE0Q34485104-762CBE23-A83B-4B44-BAC6-BE677A75F0B2Q34539785-5D3966D1-FACB-4C38-8052-D899E721049EQ34629086-4E7A1FDA-E8A5-4999-8752-BF4EB11749EEQ34641914-0C348A25-E4D5-4120-9FB1-CF0A9D137958Q35034283-67DA046E-D6A2-430A-B9FF-0C5D3688FF12Q35053650-91FC24AD-D37B-44A4-BB7A-73F64B90267DQ35366667-99249103-C7F8-48D0-9A20-3FDEDF558811Q35620244-EE3CDC6D-8C08-449F-9320-BFB243FA4ECFQ35914342-BECF16B5-0C4E-45F8-8710-6B4D68463E4BQ36168723-4FAE47E2-A0F7-4731-8FCE-366BCAFC4F8EQ36228567-2ED31E72-C491-4FB6-853D-75A5E829AB23Q36349979-8A3F7FB5-10F5-4D69-A5C0-9E54FF617E74Q36481549-818694E1-8806-412B-8185-859ECE117F43Q36590540-2521F125-3429-4000-819D-AEADF900EF31Q36669953-29AF230F-1E84-4281-B74E-E79001F210CEQ36696633-64FA4ECB-9ADF-4237-9229-F35F668AE239Q36764365-3FEB1CF9-49E0-41A2-A630-9A5B11C28EC2Q36806682-E39BA294-DEE1-43F6-A788-2CBCBC13BAA2Q36865571-05531F0B-7122-4DEE-89AD-2F80CCF145FFQ36871887-1DB56700-A26B-4E62-8ADE-06175419FB5CQ36873321-3AC57FCE-C48B-4B36-ADCC-F90C5C48BFE0Q36877989-73B0C462-693E-4D52-B097-8C4C762BA8B1Q36883146-62F0A975-997C-40BB-BF34-15A6F5B4814FQ36888549-DEF9A18C-5A2D-46FC-8F3C-C4C965D9B17AQ36901884-CDB94A99-A776-4B3B-9B84-2750DDBB5195Q36906049-F48E1A48-86D6-4B80-83DF-6ECD02794CB4Q36911884-A994D2A5-FB0F-4D6A-BEE5-42011B6D9F69Q36979271-6CEFBD34-E06B-4CCB-A110-0E8F39F24003Q37065966-4B443573-0F6B-4F42-AB58-7087DE0CC577Q37127497-CF4900F2-0A99-4A83-85EE-CD9873107D74Q37730255-CC85F74F-F18B-4A7F-9E2F-0B66C93A45F8
P2860
Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Identification and isolation o ...... utralizing antibodies in vivo.
@en
type
label
Identification and isolation o ...... utralizing antibodies in vivo.
@en
prefLabel
Identification and isolation o ...... utralizing antibodies in vivo.
@en
P2860
P1433
P1476
Identification and isolation o ...... utralizing antibodies in vivo.
@en
P2093
C A Poodry
D A Thorley-Lawson
P2860
P304
P407
P577
1982-08-01T00:00:00Z